Characterising the Neuromuscular Function of Post Stroke Patients

NCT ID: NCT07013188

Last Updated: 2025-06-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

16 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-06-01

Study Completion Date

2026-05-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Strokes are a leading cause of death and disability in developed countries, with significant economic and social impacts. Defined by the WHO, strokes cause rapid and lasting disturbances in cerebral function. In the UK, strokes occur every five minutes, affecting 100,000 people annually and resulting in substantial physical impairments and financial costs. Although stroke-related deaths have decreased due to improved treatments and awareness, strokes remain a major cause of death and disability worldwide, especially in lower-income countries. Strokes typically cause unilateral deficits, leading to significant daily challenges and necessitating tailored rehabilitation strategies such as CIMT, FES, and VR Rehab. As the population ages, innovative neurorehabilitation approaches are essential to enhance functional recovery post-stroke. This pilot study aims to better understand the neuromuscular deficits caused by stroke to inform and improve future rehabilitation interventions, including the potential use of force accuracy training (FAT)

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In developed countries, strokes are the third most common cause of death and disability. Stroke is defined by the World Health Organization (WHO) as "rapidly developed clinical signs of focal (or global) disturbance of cerebral function, lasting more than 24 hours or leading to death, with no apparent cause other than of vascular origin. In 2013, the American Heart Association added the term "silent pathology" to the definition, which includes silent haemorrhage and infarctions of the brain, spinal cord, and retina. A transient ischemic attack (TIA) is considered a "warning stroke" because although it has similar symptoms to a stroke, the symptoms last for less than 24 hours. Furthermore, approximately 50% of strokes happen within 24 hours of a TIA.

The National Institute for Health and Care Excellence (NICE) estimates that in the UK a stroke occurs once every five minutes, and 100,000 people suffer from strokes annually. Further, over 1.3 million individuals in the UK have survived a stroke, with two-thirds of these survivors leaving the hospital with some physical impairment. There are 32,000 stroke-related fatalities annually in England alone, and stroke results in an annual expenditure in the region of £26-billion across the UK. In the previous 15 years, there has been a 49% decrease in the number of deaths caused by stroke in the UK despite an ageing population and that advancing age is a clear risk factor for stroke. This is likely due to advancements in both clinical treatment pathways and public awareness.

Despite this reduction in deaths, in terms of disability-adjusted life-years lost (DALY's), stroke is still the second-highest leading cause of death and is considered to be the third-leading cause of disability globally. In 2020, one in six cardiovascular disease-related deaths were caused by strokes. Global costs associated with stroke are projected to exceed 721 billion dollars (0.66 % of the global GDP). The burden (in terms of the absolute number of cases) grew dramatically from 1990 to 2019, with the bulk of worldwide stroke burden lying in lower and lower to middle-income countries (86.0% of fatalities and 89.0% of DALY's). This rise may be linked to a 70 % increase in incident of strokes, a 44 % increase in stroke-related mortality, a 102 % increase in general strokes, and a 143 % increase in prevalent strokes. Therefore, stroke is a disease of immense importance to the global population's health, with significant repercussions for individuals, the economy and society. In the past, it was believed that stroke primarily impacted wealthy nations. In contrast, the burden of stroke has fallen dramatically in many developed countries due to the use of evidence-based management techniques.

One hallmark of stroke is its tendency to cause unilateral deficits, affecting one side of the body. This can lead to weakness, paralysis, and sensory disturbances. These deficits pose significant challenges for daily activities and can have profound psychological and social impacts. Addressing these unique features is vital in rehabilitation, where tailored interventions can improve outcomes and quality of life for stroke survivors. Some of the current stroke rehabilitation strategies include Constraint-Induced Movement Therapy (CIMT), Task-Specific Training, Functional Electrical Stimulation (FES), Robot-Assisted Therapy, Virtual Reality (VR) Rehab, and Cognitive Rehabilitation. These approaches all aim to maximize recovery and improve functional outcomes post-stroke.

As the number of stroke survivors grows due to demographic shifts in our ageing societies, novel strategies for neurorehabilitation are required. Neural reorganisation is the most important driver of functional recovery after a stroke. An enhanced knowledge of the mechanisms that enable plasticity and recovery is required for the development of novel, neurobiologically informed techniques to promote functional recovery.

In sum, a better understanding of the neuromuscular deficits caused by stroke, which will be gained from this pilot study, will allow enhanced future design of rehabilitation interventions, and will inform the consideration of force accuracy training (FAT) as a potential intervention to improve the neuromuscular and physical function of stroke patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stroke (CVA) or TIA

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Stroke patients

* Aged between 40-85 years
* Willing and able to give informed consent for participation in the study
* Had a confirmed stroke within the last 5 years
* Self-reports persisting post-stroke loss of unilateral limb function

Neuromuscular function

Intervention Type OTHER

Assessing their neuromuscular abilities using some functional and electromyography assessments

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Neuromuscular function

Assessing their neuromuscular abilities using some functional and electromyography assessments

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* • Aged between 40-85 years

* Willing and able to give informed consent for participation in the study
* Had a confirmed stroke within the last 5 years
* Self-reports persisting post-stroke loss of unilateral limb function

Exclusion Criteria

* • Diagnosis of cognitive impairment/dementia

* Current or recent (\<2y) malignancy
* Severe respiratory disease (e.g., uncontrolled asthma, COPD, pulmonary hypertension)
* Active cardiovascular disease: Uncontrolled hypertension (BP\>160/100mmHg); Recent (\<12mo) cardiac event; Heart failure (Class III/IV); Significant arrhythmia; Unstable angina
* Metabolic disease: Untreated hyper/hypoparathyroidism; Cushing's disease
* Significant musculoskeletal disorders (based on clinical opinion)
* Dialysis patients
* Recent steroid treatment within 6 months or hormone replacement therapy
* Mobility dependant (wheelchair dependency)
Minimum Eligible Age

40 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Nottingham

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Bethan Phillips

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Royal Derby Hospital branch, School of Medicine, University of Nottingham

Derby, Derbyshire, United Kingdom

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Abdulmajeed Altheyab

Role: primary

07944793209

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FMHS 188-0524

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

tDCS and Robotic Therapy in Stroke
NCT01828398 COMPLETED PHASE2